biostudies-literatureAlbertini MRBLRD VANCI NIH HHSNIH HHS307-318https://www.ebi.ac.uk/biostudies/studies/S-EPMC11444423biostudies-literatureUnknown34(4)Canine malignant melanoma provides a clinically relevant, large animal parallel patient population to study the GD2-reactive hu14.18-IL-2 immunocytokine as it is similar to human melanoma and expresses GD2. The objectives of this study were to evaluate safety, radiation fractionation, and identify informative biomarkers of an in-situ tumor vaccine involving local radiation therapy plus intratumoral-immunocytokine in melanoma tumor-bearing dogs. Twelve dogs (six dogs/arm) with locally advanced or metastatic melanoma were randomized to receive a single 8 Gy fraction (arm A) or three 8 Gy fractions over 1 week (arm B) to the primary site and regional lymph nodes (when clinically involved) with the single or last fraction 5 days before intratumoral-immunocytokine at 12 mg/m 2 on 3 consecutive Melanoma researchAdministration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma.PMC11444423P30 CA008748I01 BX003916R35 CA197078S10 OD023526P30 CA014520Shiyanbola OSondel PMKurzman IDAlbertini MRSchwartz RWRanheim EATurek MVail DMEickhoff JMorris ZSOng IMNewton MAHayim RZuleger CLfalseAdministration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma.Canine malignant melanoma provides a clinically relevant, large animal parallel patient population to study the GD2-reactive hu14.18-IL-2 immunocytokine as it is similar to human melanoma and expresses GD2. The objectives of this study were to evaluate safety, radiation fractionation, and identify informative biomarkers of an in-situ tumor vaccine involving local radiation therapy plus intratumoral-immunocytokine in melanoma tumor-bearing dogs. Twelve dogs (six dogs/arm) with locally advanced or metastatic melanoma were randomized to receive a single 8 Gy fraction (arm A) or three 8 Gy fractions over 1 week (arm B) to the primary site and regional lymph nodes (when clinically involved) with the single or last fraction 5 days before intratumoral-immunocytokine at 12 mg/m 2 on 3 consecutive 2024-01-01T00:00:00Z2024 Aug2026-03-18T13:30:05.74Z2025-08-18T09:54:15.833ZS-EPMC114444233876844210.1097/CMR.000000000000097510.1097/cmr.0000000000000975